<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460447</url>
  </required_header>
  <id_info>
    <org_study_id>EK 92062003</org_study_id>
    <nct_id>NCT00460447</nct_id>
  </id_info>
  <brief_title>Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation</brief_title>
  <official_title>Gentuzumab Ozogamicin Berfore Allogeneic Stem Cell Transplantation in Patients With Relapsed CD33+ Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Carl Gustav Carus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Carl Gustav Carus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design:&#xD;
&#xD;
      prospective phase II trial with 30 patients in 1 site&#xD;
&#xD;
      Treatment Scheme:&#xD;
&#xD;
      Option 1: Patient &lt; 60 years of age with relapse after chemotherapy or &gt; 12 months after&#xD;
      hematopoetic stem cell transplantation Mylotarg 6 mg/ m² day -21 Mylotarg 3 mg/ m² day -14&#xD;
      Fludarabin 30 mg/ m² day -6 to -3 TBI 2x2 Gy day -3 to -2 (total dose 8 Gy) Tacrolimus (level&#xD;
      adapted) from day -3 on Mycophenolat 2 x 1000 mg p.o. from day 0 to day 40 PBSC day 0&#xD;
&#xD;
      Option 2: Patient &gt; 60 years of age or younger patients &lt; 12 Months after hematopoetic stem&#xD;
      cell transplantation Mylotarg 6 mg/ m² day -21 Mylotarg 3 mg/ m² day -14 Fludarabin 30 mg/ m²&#xD;
      day -3 to -1 TBI 1x2 Gy day 0 (total dose 2 Gy) Tacrolimus (level adapted) from day -3 on&#xD;
      Mycophenolat 2 x 1000 mg p.o. from day 0 to 40 PBSC day 0&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scientific/Medical Rationale (Objective):&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      documentation of the extramedullary toxicity of the standard therapy&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
      Induction of a persistent remission by the combination of Mylotarg and dose reduced&#xD;
      conditioning followed by allogenic hematopoetic stem cell transplantation in patients with&#xD;
      relapsed acute myelotic leukemia&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      prospective phase II trial with 30 patients in 1 site&#xD;
&#xD;
      Treatment Scheme:&#xD;
&#xD;
      Option 1: Patient &lt; 60 years of age with relapse after chemotherapy or &gt; 12 months after&#xD;
      hematopoetic stem cell transplantation Mylotarg 6 mg/ m² day -21 Mylotarg 3 mg/ m² day -14&#xD;
      Fludarabin 30 mg/ m² day -6 to -3 TBI 2x2 Gy day -3 to -2 (total dose 8 Gy) Tacrolimus (level&#xD;
      adapted) from day -3 on Mycophenolat 2 x 1000 mg p.o. from day 0 to day 40 PBSC day 0&#xD;
&#xD;
      Option 2: Patient &gt; 60 years of age or younger patients &lt; 12 Months after hematopoetic stem&#xD;
      cell transplantation Mylotarg 6 mg/ m² day -21 Mylotarg 3 mg/ m² day -14 Fludarabin 30 mg/ m²&#xD;
      day -3 to -1 TBI 1x2 Gy day 0 (total dose 2 Gy) Tacrolimus (level adapted) from day -3 on&#xD;
      Mycophenolat 2 x 1000 mg p.o. from day 0 to 40 PBSC day 0&#xD;
&#xD;
      Patient Population to be Included:&#xD;
&#xD;
      30 patients&#xD;
&#xD;
      Primary and Secondary Efficacy Endpoints:&#xD;
&#xD;
      See point: Scientific/Medical Rationale&#xD;
&#xD;
      Inclusion Criteria /Exclusion Criteria:&#xD;
&#xD;
        -  patients with acute myelotic leukemia and expression of CD33 on &gt; 5% of blasts in bone&#xD;
           marrow&#xD;
&#xD;
        -  relapse after chemotherapy&#xD;
&#xD;
        -  relapse after autologous or allogenic hematopoetic stem cell transplantation&#xD;
&#xD;
        -  pts. in  2nd remission after chemotherapy and ineligible for a conventional allogeneic&#xD;
           transplantation&#xD;
&#xD;
        -  age: 18-70 years&#xD;
&#xD;
        -  informed consent of the patient&#xD;
&#xD;
        -  ASAT/ ALAT &lt; 3fold of upper standard&#xD;
&#xD;
        -  Bilirubin &lt; 2fold of upper standard&#xD;
&#xD;
        -  ejection fraction &gt; 40% in echocardiography&#xD;
&#xD;
        -  potential donor in accordance with the following priorities:&#xD;
&#xD;
        -  1st HLA-identical related donor (HLA *A, *B, *C and *DR)&#xD;
&#xD;
        -  2nd HLA-identical non-related donor with the maximum of 1 allelmismatch (DNA typing A,&#xD;
           B, C, DRB1, DQB1)&#xD;
&#xD;
      Study Procedures:&#xD;
&#xD;
      See point . Study Design&#xD;
&#xD;
      Safety Endpoints/ Statistical Considerations:&#xD;
&#xD;
      Thirty patients will be treated, which will yield a 95% confidence interval for non-relapse&#xD;
      mortality with a precision of +/- 14%. Data will be evaluated after groups of 10 and 20&#xD;
      patients. If results at those times suggest with greater than 80% confidence that the true&#xD;
      rate of day 100 non-relapse mortality exceeds 20%, then the trial will be stopped.&#xD;
      Operationally, this will occur if 4 out of 10 or 7 out of 20 patients have non-relapse&#xD;
      deaths. Should the requisite number of deaths be reached before the 10 or 20 patient&#xD;
      benchmarks, then the trial will be stopped at that time.&#xD;
&#xD;
      A dose reduction of mylotarg from 9 to 6 mg/m2 will be performed if the likelihood of grade 4&#xD;
      liver-toxicity as defined by bilirubine, AST and symptoms of sinusoidal obstruction syndrome&#xD;
      is &gt; 20%. This will be the case if 4 out of the first ten patients experience grade 4 liver&#xD;
      toxicity. The second dose of mylotarg will then be omitted in the next ten patients. If the&#xD;
      rate of liver-toxicity in the next 10 patients remains unchanged, the study will be stopped.&#xD;
&#xD;
      The stopping rules will be discussed and enforced by the protocol committee and transmitted&#xD;
      to each local IRB asap.&#xD;
&#xD;
      The following safety endpoints will be documented:&#xD;
&#xD;
        1. Incidence of neurological toxicity&#xD;
&#xD;
        2. Incidence of liver toxicity&#xD;
&#xD;
        3. Incidence of acute gastrointestinal toxicity&#xD;
&#xD;
        4. Incidence and severity of mucositis&#xD;
&#xD;
        5. Incidence of pulmonary toxicity&#xD;
&#xD;
        6. Incidence of systemic infections&#xD;
&#xD;
        7. Duration of neutropenia Severe adverse events (SAE) will have to be reported to the&#xD;
           principal investigator within 24 hours after occurrence. It will be his responsibility&#xD;
           to inform the IRB and the sponsor or the trial, if adequate.&#xD;
&#xD;
      SAE compromise: death before relapse of leukemia, illness with life-threatening character,&#xD;
      severe illness requiring hospitalization, illness leading to prolonged disabilities, second&#xD;
      cancer developing after treatment.&#xD;
&#xD;
      SAE will have to be reported on special forms contained in the CRF&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2004</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Documentation of the extramedullary toxicity of the standard therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Induction of a persistent remission by the combination of Mylotarg and dose reduced conditioning followed by allogenic hematopoetic stem cell transplantation in patients with relapsed acute myelotic leukemia</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Allogeneic Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemtuzumab Ozogamicin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - patients with acute myelotic leukemia and expression of CD33 on &gt; 5% of blasts in&#xD;
             bone marrow&#xD;
&#xD;
          -  relapse after chemotherapy&#xD;
&#xD;
          -  relapse after autologous or allogenic hematopoetic stem cell transplantation&#xD;
&#xD;
          -  pts. in 2nd remission after chemotherapy and ineligible for a conventional allogeneic&#xD;
             transplantation&#xD;
&#xD;
          -  age: 18-70 years&#xD;
&#xD;
          -  informed consent of the patient&#xD;
&#xD;
          -  ASAT/ ALAT &lt; 3fold of upper standard&#xD;
&#xD;
          -  Bilirubin &lt; 2fold of upper standard&#xD;
&#xD;
          -  ejection fraction &gt; 40% in echocardiography&#xD;
&#xD;
          -  potential donor in accordance with the following priorities:&#xD;
&#xD;
          -  1st HLA-identical related donor (HLA *A, *B, *C and *DR)&#xD;
&#xD;
          -  2nd HLA-identical non-related donor with the maximum of 1 allelmismatch (DNA typing A,&#xD;
             B, C, DRB1, DQB1)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Bornhäuser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Clinic, University Hospital Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Bornhäuser, MD</last_name>
    <phone>+49351458</phone>
    <phone_ext>4704</phone_ext>
    <email>martin.bornhaeuser@uniklinikum-dresden.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>April 12, 2007</study_first_submitted>
  <study_first_submitted_qc>April 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2007</study_first_posted>
  <last_update_submitted>April 12, 2007</last_update_submitted>
  <last_update_submitted_qc>April 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2007</last_update_posted>
  <keyword>anti-CD33</keyword>
  <keyword>Immunotoxin</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 17, 2009</submitted>
    <returned>March 13, 2009</returned>
    <submitted>March 18, 2009</submitted>
    <returned>April 23, 2009</returned>
    <submitted>April 24, 2009</submitted>
    <returned>June 11, 2009</returned>
    <submitted>June 24, 2010</submitted>
    <returned>July 22, 2010</returned>
    <submitted>September 1, 2011</submitted>
    <returned>October 3, 2011</returned>
    <submitted>June 19, 2013</submitted>
    <returned>July 22, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

